Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: Interactions with clozapine actions and attentional performance in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 4, 2008, Pages 1030-1040

  Rezvani, Amir H ^a   Tizabi, Yousef ^b   Getachew, Bruk ^b   Hauser, Sheketha R ^b   Caldwell, D Patrick ^a   Hunter, Christopher ^a   Levin, Edward D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Animal model; Attention; MK 801; Nicotinic receptors; NMDA receptors; Schizophrenia

Indexed keywords

BUNGAROTOXIN; CLOZAPINE; CYTISINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENTION; BRAIN REGION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFECT; FEMALE; FRONTAL CORTEX; NONHUMAN; OSMOTIC MINIPUMP; PERFORMANCE; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SIGNAL DETECTION;

ALKALOIDS; ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; AZOCINES; BRAIN CHEMISTRY; BUNGAROTOXINS; CLOZAPINE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; NICOTINE; NICOTINIC AGONISTS; PSYCHOMOTOR PERFORMANCE; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; SIGNAL DETECTION (PSYCHOLOGY);

EID: 42949102517     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.01.018     Document Type: Article

References (83)

1. Adler L.E., Hoffer L.D., Wiser A., and Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatr 150 (1993) 1856-1861
2. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24 (1998) 189-202
3. Amitai N., Semenova S., and Markou A. Cognitive-disruptive effects of psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology 193 (2007) 521-537
4. Barnes M., Lawford B.R., Burton S.C., Heslop K.R., Noble E.P., Hausdorf K., et al. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?. Aust N Z J Psychiatry 40 (2006) 575-580
5. 3H]MK-801 binding in rat hippocampal membranes. Neurosci Lett 296 (2000) 29-32
6. Bushnell P.J. Behavioral approaches to the assessment of attention in animals. Psychopharmacology 138 (1998) 231-259
7. Bushnell P.J., Oshiro W.M., and Padnos B.K. Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention. Psychopharmacology 134 (1997) 230-241
8. Cattapan-Ludewig K., Ludewig S., Jaquenoud Sirot E., Etzensberger M., and Hasler F. Why do schizophrenic patients smoke?. Nervenartz 76 (2005) 287-294
9. Coan R.W. Personality variables associated with cigarette smoking. J Pers Soc Psychol 26 (1973) 86-104
10. Court J.A., Lloyd S., Johnson M., Griffiths M., Birdsall N.J., Piggott M.A., et al. Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Dev Brain Res 101 (1997) 93-105
11. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73 (1999) 1590-1597
12. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatr 155 (1998) 1490-1501
13. Daniel D.G., Goldberg T.E., Weinberger D.R., Kleinman J.E., Pickar D., Lubick L.J., et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatr 153 (1996) 417-429
14. Day M., Pan J.B., Buckley M.J., Cronin E., Hollingsworth P.R., Hirst W.D., et al. Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol 73 (2007) 1123-1134
15. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., and Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha4 and beta2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41 (1992) 31-37
16. Freedman R., Hall M., Adler L.E., and Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38 (1995) 22-33
17. Galletly C.A., Clark C.R., McFarlane A.C., and Weber D.L. Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res 72 (1997) 161-166
18. Gallhofer B., Bauer U., Lis S., Krieger S., and Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6 (1996) S13-S20
19. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162 (1993) 43-48
20. Gray J.A., and Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33 (2007) 1100-1119
21. Grilly D.M., Simon B.B., and Levin E.D. Nicotine enhances stimulus detection performance of middle- and old-aged rats: a longitudinal study. Pharmacol Biochem Behav 65 (2000) 665-670
22. Harder J.A., Aboobaker A.A., Hodgetts T.C., and Ridley R.M. Learning impairments induced by glutamate blockade using dizocilpine (MK-801) in monkeys. Br J Pharmacol 125 (1998) 1013-1018
23. Hernandez C.M., and Terry Jr. A.V. Repeated nicotine exposure in rats: effects on memory function, cholinergic markers and nerve growth factor. Neuroscience 130 (2005) 997-1012
24. Hughes J.R., Hatsukami D.K., Mitchell J.E., and Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am J Psychiatr 143 (1986) 993-997
25. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatr 148 (1991) 1301-1308
26. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
27. Keefe R.S.E., Silva S.G., Perkins D.O., and Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25 (1999) 201-222
28. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64 (2007) 633-647
29. Lambe E.K., Picciotto M.R., and Aghajanian G.K. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28 (2003) 216-225
30. Lee S.M., Chou Y.H., Li M.H., Wan F.J., and Yen M.H. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuro-psychopharmacol Biol Psychiatry 31 (2007) 1101-1107
31. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., et al. Nicotinic receptor function in schizophrenia. Schizophr Bull 22 (1996) 431-445
32. Levin E.D., and Rezvani A.H. The promise of nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord 1 (2002) 423-431
33. Levin E.D., and Rezvani A.H. Nicotinic-antipsychotic drug interactions and cognitive function. In: Levin E.D. (Ed). Neurotransmitter interactions and cognitive function (2006), Birkhäuser Verlag, Berlin 185-205
34. Levin E.D., Conners C.K., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123 (1996) 55-63
35. Levin E.D., Wilson W., Rose J.E., and McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15 (1996) 429-436
36. Levin E.D., Bettegowda C., Weaver T., and Christopher N.C. Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav 61 (1998) 335-340
37. Levin E.D., Petro A., and Caldwell D.P. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-d-aspartate (NMDA) glutamatergic receptor blockade. Prog Neuro-Psychopharmacol Biol Psychiatry 29 (2005) 581-586
38. Levin E.D., Tizabi Y., Rezvani A.H., Caldwell D.P., Petro A., and Getachew B. Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding. Brain Res 1041 (2005) 132-142
39. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification and anatomic localization. Psychopharmacology 184 (2006) 523-539
40. Lichtensteiger W., Ribary U., Schlumpf M., Odermatt B., and Widmer R. Prenatal adverse effects of nicotine on the developing brain. Prog Brain Res 73 (1988) 137-157
41. Lindenmayer J.P., Iskander A., Park M., Apergi F.S., Czobor P., Smith R., et al. Clinical and neurocognitive effects of clozapine and risperidone in the treatment-refractory schizophrenics: a prospective study. J Clin Psychiatry 59 (1998) 521-527
42. Lindsley C.W., Shipe W.D., Wolkenberg S.E., Theberge C.R., Williams Jr. D.L., Sur C., et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem 6 (2006) 771-785
43. MacDonald III A.W., and Chafee M.V. Translational and developmental Perspective on N-methyl-d-aspartate synaptic deficits in schizophrenia. Dev Psychopathol 18 (2006) 853-876
44. McEvoy J.P., and Lindgren J. Smoking and schizophrenia. Drug Dev Res 38 (1996) 263-266
45. McEvoy J., Freudenreich O., McGee M., Vanderzwaag C., Levin E.D., and Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 37 (1995) 550-552
46. McGaughy J., and Sarter M. Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic differentiation: effects of physostigmine and FG 7142. Behav Neurosci 112 (1998) 1519-1525
47. McGaughy J., Decker M.W., and Sarter M. Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology 144 (1999) 175-182
48. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-255
49. Mirza N.R., and Stolerman I.P. Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology 138 (1998) 266-274
50. Mirza N.R., and Bright J.L. Nicotine-induced enhancements in the five-choice serial reaction time task in rats are strain-dependent. Psychopharmacology 154 (2001) 8-12
51. Morrison P.D., and Pilowsky L.S. Schizophrenia: more evidence for less glutamate. Expert Rev Neurotherapeutics 7 (2007) 29-31
52. Murrin L.C., Ferrer J.R., Wanyun Z., and Haley N.J. Nicotine administration to rats: methodological considerations. Life Sci 40 (1987) 1699-1708
53. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49 (2001) 200-210
54. Nordberg A., Alafuzoff I., and Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 31 (1992) 103-111
55. O'grada C., and Dinan T. Executive function in schizophrenia: what impact do antipsychotics have?. Hum Psychopharmacol 22 (2007) 397-406
56. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 39 (1991) 9-12
57. Rasmussen B., O'Neil J., Manaye K.F., Perry D.C., and Tizabi Y. Long-term effects of developmental PCP administration on auditory gating in male and female rats. Psychopharmacology 190 (2007) 43-49
58. Rezvani A.H., and Levin E.D. Cognitive effects of nicotine. Biol Psychiatry 49 (2001) 258-267
59. Rezvani A.H., and Levin E.D. Nicotine interactions with the NMDA glutaminergic antagonist dizocilpine and attentional function. Eur J Pharmacol 465 (2003) 83-90
60. Rezvani A.H., and Levin E.D. Nicotine-alcohol interactions and attentional performance on an operant visual signal detection task in female rats. Pharmacol Biochem Behav 76 (2003) 75-83
61. Rezvani A.H., and Levin E.D. Nicotine-antipsychotic drug interactions and attentional performance in female rats. Eur J Pharmacol 486 (2004) 175-182
62. Rezvani A.H., Bushnell P., and Levin E.D. Nicotine and mecamylamine effects on choice accuracy in an operant signal detection task. Psychopharmacology 164 (2002) 369-375
63. Rezvani A.H., Caldwell D., and Levin E.D. Nicotine-antipsychotic drug interactions and attentional performance. Eur J Pharmacol 486 (2004) 175-182
64. Rezvani A.H., Caldwell D.P., and Levin E.D. Nicotine-serotonergic drug interactions and attentional performance in rats. Psychopharmacology 179 (2005) 521-528
65. Rezvani A.H., Caldwell D.P., and Levin E.D. Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. Prog Neuro-Psychopharmacol Biol Psychiatry 30 (2006) 190-197
66. Rezvani A.H., Kholdebarin E., Dawson E., and Levin E.D. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. Int J Neuropsychopharmacol 11 (2008) 63-70
67. Richardson S.A., and Tizabi Y. Hyperactivity in the offspring of nicotine-treated rats: role of the mesolimbic and nigrostriatal dopaminergic pathways. Pharmacol Biochem Behav 47 (1994) 331-337
68. Sarter M., Givens B., and Bruno J.P. The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brains Res Rev 35 (2001) 146-160
69. Semenova S., Stolerman I.P., and Markou A. Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav 87 (2007) 360-368
70. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299 (2001) 782-792
71. Stip E. Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Can J Psychiatry 41 (1996) S27-S34
72. Stip E. Cognition, schizophrenia, and the effects of antipsychotics. Encephale 32 3 Pt 1 (2006) 341-350
73. Stolerman I.P., Mirza N.R., Hahn B., and Shoaib M. Nicotine in an animal model of attention. Eur J Pharmacol 393 (2000) 147-154
74. Terry Jr. A.V., Risbrough V.B., Buccafusco J.J., and Menzaghi F. Effects of (±)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J Pharmacol Exp Ther 301 (2002) 284-292
75. Tizabi Y. Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia. Neurotox Res 12 (2007) 233-246
76. Tizabi Y., Overstreet D.H., Rezvani A.H., Louis V.A., Clark E., and Janowsky D.S. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 142 (1999) 158-164
77. Trauth J.A., Seidler F.J., McCook E.C., and Slotkin T.A. Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. Brain Res 851 (1999) 9-19
78. Tsukada H., Miyasato K., Nishiyama S., Fukumoto D., Kakiuchi T., and Domino E.F. Nicotine normalizes increased prefrontal cortical dopamine D1 receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: a PET study in conscious monkeys. Neuropsychopharmacology 30 (2005) 2144-2153
79. Waldo M.C., Adler L.E., Leonard S., Olincy A., Ross R.G., Harris J.G., et al. Familial transmission of risk factors in the first-degree relatives of schizophrenic people. Biol Psychiatry 47 (2000) 231-239
80. Wang B.W., Liao W.N., Chang C.T., and Wang S.J. Facilitation of glutamate release by nicotine involves the activation of a Ca2+/calmodulin signaling pathway in rat prefrontal cortex nerve terminals. Synapse 15 (2006) 491-501
81. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177 (2004) 207-216
82. Weiss S., Nosten-Bertrand M., McIntosh J.M., Giros B., and Martres M.P. Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance. Neuropsychopharmacology 32 (2007) 2465-2478
83. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Wu G.Y., Cao L.Y., et al. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 27 (2007) 246-251